

=====

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2010; month=3; day=26; hr=14; min=33; sec=22; ms=714;]

=====

Application No: 10587987

Version No: 2.0

Input Set:**Output Set:****Started:** 2010-03-16 19:17:08.382**Finished:** 2010-03-16 19:17:16.576**Elapsed:** 0 hr(s) 0 min(s) 8 sec(s) 194 ms**Total Warnings:** 56**Total Errors:** 82**No. of SeqIDs Defined:** 56**Actual SeqID Count:** 56

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2010-03-16 19:17:08.382

Finished: 2010-03-16 19:17:16.576

Elapsed: 0 hr(s) 0 min(s) 8 sec(s) 194 ms

Total Warnings: 56

Total Errors: 82

No. of SeqIDs Defined: 56

Actual SeqID Count: 56

Error code	Error Description
	This error has occurred more than 20 times, will not be displayed
E 341	'Xaa' position not defined SEQID (26) POS (6)
E 341	'Xaa' position not defined SEQID (26) POS (7)
E 341	'Xaa' position not defined SEQID (26) POS (8)
E 341	'Xaa' position not defined SEQID (27) POS (9)
E 341	'Xaa' position not defined SEQID (27) POS (10)
E 341	'Xaa' position not defined SEQID (30) POS (2)
E 341	'Xaa' position not defined SEQID (30) POS (3)
E 341	'Xaa' position not defined SEQID (30) POS (4)
E 341	'Xaa' position not defined SEQID (31) POS (2)
E 341	'Xaa' position not defined SEQID (31) POS (3)
E 341	'Xaa' position not defined SEQID (31) POS (4)
E 341	'Xaa' position not defined SEQID (32) POS (6)
E 341	'Xaa' position not defined SEQID (32) POS (7)
E 341	'Xaa' position not defined SEQID (32) POS (8)
E 341	'Xaa' position not defined SEQID (32) POS (9)
E 341	'Xaa' position not defined SEQID (32) POS (10)
E 341	'Xaa' position not defined SEQID (34) POS (2)
E 341	'Xaa' position not defined SEQID (34) POS (3)
E 341	'Xaa' position not defined SEQID (34) POS (4)
E 341	'Xaa' position not defined SEQID (35) POS (2)
	This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> Mixture Sciences, Inc.
The Government of the United States of America, as Represented by the
Secretary, Department of Health and Human Services
Houghten, Richard A.
Pinilla, Clemencia
Martin, Roland
Sturzebecher, Claus-Steffen
Shukaliak-Quandt, Jaqueline
McFarland, Henry F.

<120> PEPTIDE MIXTURES WITH IMMUNOMODULATORY
ACTIVITY

<130> MCI.003NP

<140> 10587987
<141> 2010-03-16

<150> PCT/US2005/002962
<151> 2005-02-02

<150> 60/541,397
<151> 2004-02-02

<160> 56

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide

<220>
<221> VARIANT
<222> 1
<223> Xaa = F or W

<220>
<221> VARIANT
<222> 2
<223> Xaa = E or F

<220>
<221> VARIANT
<222> 3
<223> Xaa = E or K

<220>

<221> VARIANT
<222> 4
<223> Xaa = A, E or K

<220>
<221> VARIANT
<222> 5
<223> Xaa = A, K or Y

<220>
<221> VARIANT
<222> (6) ... (7)
<223> Xaa = A, N or Y

<220>
<221> VARIANT
<222> (8) ... (8)
<223> Xaa = A, I, N or V

<220>
<221> VARIANT
<222> (9) ... (9)
<223> Xaa = A, S or V

<400> 1
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr
1 5 10

<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide

<220>
<221> VARIANT
<222> 1
<223> Xaa = E, F, W or Y

<220>
<221> VARIANT
<222> 2
<223> Xaa = E, F, I, V, W or Y

<220>
<221> VARIANT
<222> 3
<223> Xaa = E, F, K or Q

<220>

<221> VARIANT
<222> 4
<223> Xaa = A, E, K or Q

<220>
<221> VARIANT
<222> 5
<223> Xaa = A, K, Q or Y

<220>
<221> VARIANT
<222> (6) ... (6)
<223> Xaa = A, N, Q or Y

<220>
<221> VARIANT
<222> (7) ... (7)
<223> Xaa = A, G, N, S or Y

<220>
<221> VARIANT
<222> (8) ... (8)
<223> Xaa = A, G, I, N, S or V

<220>
<221> VARIANT
<222> (9) ... (9)
<223> Xaa = A, I, Q, S or V

<220>
<221> VARIANT
<222> (10) ... (10)
<223> Xaa = I, K, R, S, V or Y

<400> 2
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide

<400> 3
Glu Tyr Tyr Lys Glu Tyr Tyr Lys Glu Tyr Tyr Lys
1 5 10

<210> 4
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide PLP 89-106

<400> 4
Gly Phe Tyr Thr Thr Gly Ala Val Arg Gln Ile Phe Gly Asp Tyr Lys
1 5 10 15
Thr Thr

<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide PLP 139-154

<400> 5
His Cys Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe Val Gly Ile
1 5 10 15

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide PLP 178-197

<400> 6
Asn Thr Trp Thr Thr Cys Gln Ser Ile Ala Phe Pro Ser Lys Thr Ser
1 5 10 15
Ala Ser Ile Gly
20

<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide PLP 190-209

<400> 7
Ser Lys Thr Ser Ala Ser Ile Gly Ser Leu Cys Ala Asp Ala Arg Met
1 5 10 15
Tyr Gly Val Leu
20

<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MBP 13-32

<400> 8
Lys Tyr Leu Ala Thr Ala Ser Thr Met Asp His Ala Arg His Gly Phe
1 5 10 15
Leu Pro Arg His
20

<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MBP 83-99

<400> 9
Glu Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg Thr
1 5 10 15
Pro

<210> 10
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MBP 111-129

<400> 10
Leu Ser Arg Phe Ser Trp Gly Ala Glu Gly Gln Arg Pro Gly Phe Gly
1 5 10 15
Tyr Gly Gly

<210> 11
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MBP 131-155

<400> 11
Ala Ser Asp Tyr Lys Ser Ala His Lys Gly Leu Lys Gly Val Asp Ala

1	5	10	15						
Gln	Gly	Thr	Leu	Ser	Lys	Ile	Phe	Lys	
		20				25			

<210> 12
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MBP 146-170

<400> 12															
Ala	Gln	Gly	Thr	Leu	Ser	Lys	Ile	Phe	Lys	Leu	Gly	Gly	Arg	Asp	Ser
1				5				10					15		
Arg	Ser	Gly	Ser	Pro											
				20											

<210> 13
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MOG 1-20

<400> 13															
Cys	Gln	Phe	Arg	Val	Ile	Gly	Pro	Arg	His	Pro	Ile	Arg	Ala	Leu	Val
1				5				10					15		
Gly	Asp	Glu	Val												
				20											

<210> 14
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MOG 11-30

<400> 14															
Pro	Ile	Arg	Ala	Leu	Val	Gly	Asp	Glu	Val	Glu	Leu	Pro	Cys	Arg	Ile
1				5				10					15		
Ser	Pro	Gly	Lys												
				20											

<210> 15
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MOG 21-40

<400> 15
Glu Leu Pro Cys Arg Ile Ser Pro Gly Lys Asn Ala Thr Gly Met Glu
1 5 10 15
Val Gly Trp Tyr
20

<210> 16
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide MOG 35-55

<400> 16
Met Glu Val Gly Trp Tyr Arg Pro Pro Phe Ser Arg Val Val His Leu
1 5 10 15
Tyr Arg Asn Gly Lys
20

<210> 17
<211> 31
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide CNPase 343-373

<400> 17
Glu Val Gly Glu Leu Ser Arg Gly Lys Leu Tyr Ser Leu Gly Asn Gly
1 5 10 15
Arg Trp Met Leu Thr Leu Ala Lys Asn Met Glu Val Arg Ala Ile
20 25 30

<210> 18
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide CNPase 356-388

<400> 18
Gly Asn Gly Arg Trp Met Leu Thr Leu Ala Lys Asn Met Glu Val Arg
1 5 10 15
Ala Ile Phe Thr Gly Tyr Tyr Gly Lys Gly Lys Pro Val Pro Thr Gln
20 25 30
Gly

<210> 19
<211> 19

<212> PRT
 <213> Artificial Sequence

 <220>
 <223> Artificially Synthesized Peptide MOBP 21-39

 <400> 19
 Phe Ser Ile His Cys Cys Pro Pro Phe Thr Phe Asn Asn Ser Lys Lys
 1 5 10 15
 Glu Ile Val

 <210> 20
 <211> 19
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Artificially Synthesized Peptide MOBP 31-49

 <400> 20
 Phe Leu Asn Ser Lys Lys Glu Ile Val Asp Arg Lys Tyr Ser Ile Cys
 1 5 10 15
 Lys Ser Gly

 <210> 21
 <211> 13
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Artificially Synthesized Peptide PLP 139-151

 <400> 21
 His Ser Leu Gly Lys Trp Leu Gly His Pro Asp Lys Phe
 1 5 10

 <210> 22
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Artificially Synthesized Peptide AEKY-10

 <220>
 <221> VARIANT
 <222> (1)...(10)
 <223> Xaa = A, E, K or Y

 <400> 22
 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 1 5 10

 <210> 23
 <211> 11
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Artificially Synthesized Peptide MOBP 1-20

 <400> 23
 Phe Ser Ile His Cys Cys Pro Pro Phe Thr Phe Asn Asn Ser Lys Lys
 1 5 10 15
 Glu Ile Val Asp Arg Lys Tyr Ser Ile Cys
 20 21 22 23

<210> 23
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-12

<220>
<221> VARIANT
<222> (1)...(12)
<223> Xaa = A, E, K or Y

<400> 23
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 24
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-15

<220>
<221> VARIANT
<222> (1)...(15)
<223> Xaa = A, E, K or Y

<400> 24
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

<210> 25
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-20

<220>
<221> VARIANT
<222> (1)...(20)
<223> Xaa = A, E, K or Y

<400> 25
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20

<210> 26
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-10-DR2a

<220>
<221> VARIANT
<222> 1
<223> Xaa = F, L, M or Y

<220>
<221> VARIANT
<222> 2-3, 5-8, 10
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 4
<223> Xaa = I, M, Q or V

<220>
<221> VARIANT
<222> 9
<223> Xaa = K or R

<400> 26
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 27
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-10-DR2b

<220>
<221> VARIANT
<222> 1
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 2-3, 5-6, 8-10
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 4
<223> Xaa = I, M, Q or V

<213> Artificial Sequence

<220>
<221> VARIANT
<222> 7
<223> Xaa = F, I, L, M or V

<400> 27
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 28
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide GA TCC-1-10

<220>
<221> VARIANT
<222> 1
<223> Xaa = F or W

<220>
<221> VARIANT
<222> 2
<223> Xaa = E or F

<220>
<221> VARIANT
<222> 3
<223> Xaa = E or K

<220>
<221> VARIANT
<222> 4
<223> Xaa = A, E or K

<220>
<221> VARIANT
<222> 5
<223> Xaa = A, K or Y

<220>
<221> VARIANT
<222> (6) ... (7)
<223> Xaa = A, N or Y

<220>
<221> VARIANT
<222> (8) ... (8)
<223> Xaa = A, I, N or V

<220>
<221> VARIANT
<222> (9) . . . (9)
<223> Xaa = A, S or V

<400> 28
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr
1 5 10

<210> 29
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide GA TCC-2-10

<220>
<221> VARIANT
<222> 1
<223> Xaa = E, F, W or Y

<220>
<221> VARIANT
<222> 2
<223> Xaa = E, F, I, V, W or Y

<220>
<221> VARIANT
<222> 3
<223> Xaa = E, F, K or Q

<220>
<221> VARIANT
<222> 4
<223> Xaa = A, E, K or Q

<220>
<221> VARIANT
<222> 5
<223> Xaa = A, K, Q or Y

<220>
<221> VARIANT
<222> (6) . . . (6)
<223> Xaa = A, N, Q or Y

<220>
<221> VARIANT
<222> (7) . . . (7)
<223> Xaa = A, G, N, S or Y

<220>
<221> VARIANT
<222> (8)...(8)
<223> Xaa = A, G, I, N, S or V

<220>
<221> VARIANT
<222> (9)...(9)
<223> Xaa = A, I, Q, S or V

<220>
<221> VARIANT
<222> (10)...(10)
<223> Xaa = I, K, R, S, V or Y

<400> 29
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 30
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide 19a.a.-10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,
T, V, W or Y

<220>
<221> VARIANT
<222> 5
<223> Xaa = K, H, R or V

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 31
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 5
<223> Xaa = K, H, R or V

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 31
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 32
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY-10-IAs-mis

<220>
<221> VARIANT
<222> 1
<223> Xaa = P or I

<220>
<221> VARIANT
<222> 2
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 3
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 4
<223> Xaa = K, H, R or V

<220>
<221> VARIANT
<222> 5-10
<223> Xaa = A, E, K or Y

<400> 32
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 33
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide 19 a.a.-10

<220>
<221> VARIANT
<222> (1)...(10)
<223> Xaa = A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R,
T, V, W or Y

<400> 33
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 34
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 34
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 35
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 35
Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 36
<211> 10
<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 36

Xaa	Xaa	Xaa	Xaa	Asp	Xaa	Xaa	Xaa	Xaa	Xaa
1				5					10

<210> 37

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT

<222> 1-4, 6, 9

<223> Xaa = A, E, K or Y

<220>

<221> VARIANT

<222> 7

<223> Xaa = I, L or V

<220>

<221> VARIANT

<222> 8

<223> Xaa = H, R or K

<220>

<221> VARIANT

<222> 10

<223> Xaa = P or I

<400> 37
Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 38
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 38
Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 39
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 39
Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 40
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>
<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 40
Xaa Xaa Xaa Xaa His Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 41
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificially Synthesized Peptide AEKY10-IAs

<220>

<221> VARIANT
<222> 1-4, 6, 9
<223> Xaa = A, E, K or Y

<220>
<221> VARIANT
<222> 7
<223> Xaa = I, L or V

<220>
<221> VARIANT
<222> 8
<223> Xaa = H, R or K

<220>
<221> VARIANT
<222> 10
<223> Xaa = P or I

<400> 41
Xaa Xaa Xaa Xaa Ile Xaa Xaa Xa